Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasmsClodagh Keohane, Ruben Mesa, Claire HarrisonBiologics : Targets & Therapy|August 31, 2013
Treatment and management of myelofibrosis in the era of JAK inhibitorsClodagh Keohane, Deepti H Radia, Claire N HarrisonBMJ Case Reports|January 1, 2022
High grade non-germinal centre-like diffuse large B-cell lymphoma double expressor presenting as a hydrocoeleDonnacha Hogan, Brian Hayes, Clodagh Keohane, et al.Expert Review of Hematology|October 3, 2013
Practical management of patients with myelofibrosis receiving ruxolitinibClaire Harrison, Ruben Mesa, David Ross, et al.Haematologica|September 24, 2013
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinibBridget S Wilkins, Deepti Radia, Claire Woodley, et al.British Journal of Haematology|June 16, 2015
JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cellsClodagh Keohane, Shahram Kordasti, Thomas Seidl, et al.British Journal of Haematology|May 16, 2019
Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experienceJoana Desterro, Donal P McLornan, Natalia Curto Garcia, et al.British Journal of Haematology|May 7, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysisAlexandros Rampotas, Matthew R Wilson, Oliver Lomas, et al.Pageof 1